Evidence map›Paper›PMID 26691425›Full record

ReviewBone marrow transplantation2016

Venous thromboembolism in hematopoietic stem cell transplant recipients.

S Chaturvedi, A Neff, A Nagler, U Savani, M Mohty, B N Savani

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05396157 (Venous Thromboembolism in Hematologic Malignancy and Hematopoietic Cell Transplant Patients), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05396157 active not recruitingnot on this mapstarted 2021, after this paper: background citation

Venous Thromboembolism in Hematologic Malignancy and Hematopoietic Cell Transplant Patients: a Retrospective Study of Thrombosis / Bleeding Incidence and Prophylaxis Trends

TypeobservationalSponsorMount Sinai Hospital, CanadaRan2021 to 2026Enrolled813ConditionsThrombosis, Venous, Bleeding Hemorrhage, Venous Thromboembolic Disease, Hematologic Malignancy
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018
    Article
  12. Venous Thrombosis in Hematopoietic Stem Cell Transplantation.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2017
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

S ChaturvediHematology and Stem Cell Transplantation Section, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center and Veterans Affairs Medical Center, Nashville, TN, USA.
A NeffBenign Hematology Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, OH, USA.
A NaglerHematology Division, Department of Medicine, Chaim Sheba Medical Center, Tel Hahomer, Israel.
U SavaniUniversity of Michigan, Ann Arbor, MI, USA.
M MohtyDepartment of Haematology, Saint Antoine Hospital, Paris, France.
B N SavaniHematology and Stem Cell Transplantation Section, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center and Veterans Affairs Medical Center, Nashville, TN, USA.
Vanderbilt University Medical Center · USCleveland Clinic · USSheba Medical Center · ILSorbonne Université · FRUniversity of Michigan–Ann Arbor · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Venous thromboembolism (VTE) is an increasingly recognized problem in the post-hematopoietic stem cell transplantation (HSCT) setting, with a lack of high-quality evidence-based data to recommend best practices. Few patients with hematologic malignancies and even fewer post-HSCT patients were included in randomized trials of VTE prophylaxis and treatment. Prior VTE, GVHD, infections and indwelling venous catheters are risk factors for thrombosis. The increasing use of post-transplant maintenance therapy with lenalidomide in patients with multiple myeloma adds to this risk after autologous HSCT. These patients are also at high risk of bleeding complications because of prolonged thrombocytopenia and managing the competing risks of bleeding and thrombosis can be challenging. This review aims to provide a practical, clinician-focused approach to the prevention and treatment of VTE in the post-HSCT setting.

Indexed as

AllograftsGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansLenalidomideMultiple MyelomaPostoperative ComplicationsThalidomideVenous ThromboembolismLenalidomideThalidomide

Identifiers

PMID26691425
OpenAlexW2205448807

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.